Londamocitinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Londamocitinib
- Molecular weight
- 599.66
- Structure (SMILES)
- COC[C@H](C(=O)Nc1cccc2c(-c3nc(Nc4cccc(S(C)(=O)=O)c4F)ncc3F)c[nH]c12)N1CCN(C)CC1
- (R)-N-(3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide
- azd 4604
- AZD-4604
- azd4604
- Azd4604
- AZD4604
- londamocitinib
- Londamocitinib
- londamocitinib [INN]
- LONDAMOCITINIB [USAN]
- Londamocitinib [WHO-DD]
- londamocitinib inn
- londamocitinib usan
- londamocitinib who dd
- r n 3 5 fluoro 2 2 fluoro 3 methylsulfonyl phenyl amino pyrimidin 4 yl 1h indol 7 yl 3 methoxy 2 4 methylpiperazin 1 yl propanamide
- CAS registry numbers
- 2241039-81-4
- ChEMBL ID
- CHEMBL4447181
- InChIKey
- JNUZADQZHYFJGW-JOCHJYFZSA-N
- PubChem compound IDs
- 135240395
- FDA ingredient codes (UNII)
- JAC34RRR7S
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- londamocitinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Janus kinase 2
- Gene symbol
- JAK2
- Protein identifier
- O60674
- Median affinity
- 5.91
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- Janus kinase 1
- Gene symbol
- JAK1
- Protein identifier
- P23458
- Median affinity
- 8.52
- Affinity units
- pIC50
Open Targets indications
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 2
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 3
- Polar surface area
- 132.55
- Calculated partition coefficient (ALogP)
- 3.25
- Calculated partition coefficient (XLogP)
- 2.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 9
- Heavy atoms
- 42
- Molecular formula
- C28H31F2N7O4S
- Monoisotopic mass
- 599.21262999
- Natural product
- No
- Recorded assays
- 56
- Active assays
- 14
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (6)
- A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of Asthma
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled AZD4604 in Healthy Japanese and Chinese Participants.
- An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604
- Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
- Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma
- Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma.
In development for (1)
- Asthma Phase 2